Mylan Generic Treads On AstraZeneca Patents, Fed. Circ. Hears
In June, the Delaware court ruled AstraZeneca hadn't done enough to prove Mylan's generic violated U.S. Patent Numbers 6,423,340 and 5,643,602. The patents cover a method and oral composition for the treatment of inflammatory bowel diseases, such as Crohn's disease.
AstraZeneca alleged Thursday that Mylan had misconstrued its...
To view the full article, register now.